Small-Cap Catalysts to Watch: April 28 - May 2

We’ve reviewed the latest filings and press releases to highlight the key catalysts and upcoming conferences for this week. Stay informed and stay ahead. ***Check out last week's article for the list of companies still scheduled to present at the AACR Annual Meeting 2025 (April 25–30, McCormick Place, Chicago, IL).

Companies with key catalysts this week:

TARA > The company will hold a conference call and webcast on April 28, 2025, at 8:30 a.m. ET to discuss updated safety and efficacy data from the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC patients, including 12-month evaluation data.

ELVA > The company will exhibit at the Advanced Clean Transportation (ACT) Expo 2025, held from April 28-30, 2025, at the Anaheim Convention Center in California.

MULN > Its subsidiary, Bollinger Motors, will debut the first upfitted Bollinger B4 truck at the Advanced Clean Trucking (ACT) Expo 2025 in Anaheim, California, from April 28 to May 1. Additional trucks will be deployed in California to offer reliable mobile charging solutions for the growing EV infrastructure demand.

PROF > A hybrid (in-person and virtual) investor event will take place on Monday, April 28, 2025, during the American Urological Association's (AUA) Annual Meeting.

HYLN > will participate in the Advanced Clean Transportation (ACT) Expo 2025 from April 28 – May 1 at the Anaheim Convention Center in California. They will exhibit at Booth #6205, showcasing the KARNO Power Module, a fuel-agnostic system designed to transform power generation. Additionally, Hyliion will host a press event on April 29 at 12:30 PM PT, inviting media, industry professionals, and attendees to learn about the innovative capabilities of the KARNO Power Module.

HOVR > Trickle Research Microcap Conference: Spring 2025, April 28, 2025, Denver: Mr. Robinson will deliver an investor presentation and participate in Q&A.

OXBR > The company will participate in TOKEN2049 Dubai, one of the world's leading blockchain events, happening from April 30 to May 1, 2025, at the Madinat Jumeirah in Dubai, UAE.

DARE > Sabrina Martucci Johnson, President and CEO, will deliver a keynote at the Fierce Pharma Engage summit on April 29, 2025, at 4:30 p.m. PT. Her address, "Breaking Barriers, Building Access: Communicating Bold Moves in Women's Health Innovation," will focus on Daré's strategy to integrate 503B compounding and bring proprietary formulations, including Sildenafil Cream, to market, highlighting the role of strategic messaging in conveying innovative business strategies.

QUIK > Will present and exhibit at the Andes RISC-V CON Technology Summit in San Jose on April 29th. The presentation, led by Vice President of IP Sales Andy Jaros, will highlight the use of embedded FPGA (eFPGA) technology to customize embedded RISC-V processing solutions from Andes Technology.

BDSX > Will present the latest advancements in ctDNA testing, using ddPCR technology, at the American Association for Cancer Research (AACR) Annual Meeting on April 28th, 2025. The company is also exploring the combination of ctDNA and proteomics to detect molecular residual disease (MRD) as part of its Development Services portfolio.

ELUT > Will participate in Chardan's Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.

ANRO > Members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings.

PSNL > Two oral presentations and a poster presentation featuring data on the company's NeXT Personal® ultrasensitive ctDNA assay for detecting residual and recurrent cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 28-29, 2025.

VERU > The Company will present at the 2nd Annual GLP-1-Based Therapeutics Summit, taking place April 29 - May 1, 2025, in Boston, Massachusetts.

SES > Will host a live demo on April 29, 2025, at 11 a.m. ET to unveil Molecular Universe MU-0 its latest battery material discovery software and service platform, powered by physics and AI.

AREC > Will be presenting at Battery Innovation Center (BIC) Industry Luncheon: April 29, 2025.

KAPA > Scheduled to participate in the Fierce Pharma Engage Business Development and Licensing Meeting in San Diego from April 29 to May 1, 2025.

AUTL > Abstracts featuring data on obe-cel in adult ALL, including a sub-analysis of patients aged 55 and older, were accepted for presentation at the British Society for Haematology Annual Meeting in Glasgow, UK (April 27-29, 2025).

EPRX > The Company will present Phase 1b data on EP-104GI for eosinophilic esophagitis at the DDW Annual Meeting in San Diego, May 3-6, 2025. Dr. Evan Dellon and Dr. Amanda Malone will present posters on the study and esophageal strictures on May 3.

IMTX > The Company will present data on its lead cell therapy candidate, IMA203 targeting PRAME, at the 2025 ASCO Annual Meeting from May 30 – June 3 in Chicago.

GPUS > BitNile.com, the Company’s indirectly wholly owned subsidiary, plans to launch its own Nile Coin on the Solana blockchain on May 1, 2025, with further updates on its utility to follow.

CLOV > CFO, Peter Kuipers, will participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 28, 2025.

DSGN > Will present an update on its DT-168 program for Fuchs endothelial corneal dystrophy at Eyecelerator @ Park City 2025 on May 2, including Phase 1 safety findings and Phase 2 development plans.

CALC > will present a poster at DDW 2025 titled Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS) Have a Larger Volume of Distribution Compared to Healthy Volunteers. The presentation by co-Founder and Chief Scientific Officer Kenneth A. Stauderman, Ph.D., will take place during the "Clinical Acute Pancreatitis: Management" session on Saturday, May 3, from 12:30–1:30 p.m. PT.

PDSB > Three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology ("ASCO") Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois.

VEEE > BoatsForSale.com is currently undergoing its final migration to Twin Vee's robust, scalable architecture powered by Microsoft Azure and AI Foundry tools, with the full transition expected to be complete no later than May 1, 2025.

IRD > Will present new one-year data from its ongoing Phase 1/2 trial of OPGx-LCA5 at the ARVO 2025 Meeting on May 4, showing that visual improvements observed in all three adult patients at six months persisted over a year, providing preliminary evidence of sustained efficacy.

UNCY > Will present patient reported outcomes data from its pivotal UNI-OLC-201 study on oxylanthanum carbonate (OLC) for hyperphosphatemia treatment at the 2025 ANNA National Symposium, being held May 1–4.

PALI > Will present data from its lead program, PALI-2108 for ulcerative colitis, at Digestive Disease Week® (DDW) 2025 on May 4-5th in San Diego.

KPRX > Data supporting KIO-104 for preventing and treating PVR has been accepted for poster presentation at the ARVO meeting in Salt Lake City on May 4, 2025.

RDI > Signed a Put & Call Option with attached purchase and sale contracts to sell our Cannon Park properties for AU$32.0 million, targeting a closing before the end of April 2025. The buyer has posted a AU$1.6 million deposit, but the sale remains subject to due diligence. The deal also includes a long-term leaseback to Reading Cinemas.

NURO > The company expects to complete the merger in the last week of April 2025, subject to the satisfaction of closing conditions, including the determination of Net Cash as defined in the Merger Agreement and the filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2024.

SCPH > FUROSCIX was approved by the FDA on March 6, 2025, for the treatment of edema in patients with chronic kidney disease (CKD). scPharmaceuticals plans to officially launch the new indication in April 2025 and has completed key pre-launch activities, including engagement with key opinion leaders, market research, and commercial readiness preparations.

DTCK > On February 24, 2025, the company signed a Memorandum of Understanding (MOU) with Carfax Commodities (Asia) Pte Ltd, a global leader in food commodities trading, to initiate a strategic share acquisition plan. This collaboration is expected to create significant synergies and growth opportunities for both parties. The finalization of the key commercial terms for the proposed transaction is set for April 30, 2025.

NLSP > The Merger Agreement includes standard termination rights for both NLS and Kadimastem, allowing either party to terminate the agreement if the closing does not occur by a specified outside date, which can be extended by mutual consent. The original outside date was January 31, 2024, but it has been extended to April 30, 2025, through an amendment.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.